Ocrelizumab-treated patients with relapsing multiple sclerosis show volume loss rates similar to healthy aging.
Shannon KolindLaura GaetanoHaz-Edine AssemlalCorrado BernasconiUlrike BonatiColm ElliottNiels HagenbuchStefano MagonDouglas L ArnoldAnthony TraboulseePublished in: Multiple sclerosis (Houndmills, Basingstoke, England) (2023)
These findings are consistent with an important role of inflammation on overall tissue loss and the role of ocrelizumab in reducing this phenomenon.